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Abstract 
The question of whether diet plays a role in the onset of Ankylosing spondylitis (AS), or can 
affect the course of disease is an important one for many patients and health care providers. 
The aims of the study were to investigate whether: 1) patients with AS report different diet to 
those without; 2) amongst patients with AS diet is related to severity; 3) persons with particular 
diets are less likely to develop AS; 4) specific dietary interventions improve symptoms of AS. 
The review was conducted according to PRISMA guidelines. Medline, Embase, Cochrane 
Library and reference lists of relevant articles were searched. Two authors independently 
selected eligible studies, assessed quality of included trials and extracted data. 
Sixteen studies (9 observational and 7 intervention) were included in the review. Due to the 
heterogeneity of study designs and analyses, the results could not be pooled. 
Evidence on a possible relationship between AS and diet is extremely limited and inconclusive 
due to the majority of included studies being small, single studies with moderate to high risk of 
bias and insufficient reporting results. 
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Introduction 
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease with estimated 
prevalence per 10,000 of 23.8 in Europe, 16.7 in Asia, 31.9 in North America, 10.2 in Latin 
America and 7.4 in Africa (1). AS adversely affects patients in terms of symptoms such as pain 
and fatigue leading to impaired function and diminished quality of life (2,3). Despite the 
development of biologic therapy, which has revolutionised the treatment of AS (4), many 
patients explore complementary treatments such as dietary therapy.  
There is overwhelming evidence of the importance of diet in the aetiology of a wide range of 
diseases such as rheumatoid arthritis (RA), cardiovascular disease and cancer (5,6,7). An 
examination of dietary patterns in a large cohort of nurses in the United States found that dietary 
patterns characterised by high intakes of fruit, vegetables, legumes, whole grains, poultry, and 
fish, was associated with a reduced risk of RA. In contrast, dietary patterns typical of 
industrialised countries (high intake of red meats, processed meats, refined grains, French fries, 
desserts and sweets, and high-fat dairy products) was associated with an increased risk of RA 
(8). A meta-analysis of placebo-controlled trials in patients with RA reported that that dietary fish 
oil has a modest effect in reducing tender joint count and morning stiffness (9), an effect 
attributed to the anti-inflammatory mechanism of omega-3 polyunsaturated fatty acids.  
It has been suggested (10,11,12,13) that low starch diet leads to lower AS disease activity and 
that Klebsiella pneumoniae, which can be influenced by starch consumption, is a triggering 
factor involved in the initiation and development of AS (12).  
Although some publications have considered the evidence linking AS with diet 
(14,15,16,17,18,19), there have been no systematic evaluations of the evidence. 
The objectives of this systematic review were to investigate whether: 
1) patients with AS report different diet to those without. 
2) amongst patients with AS diet is related to severity. 
3) persons with particular diets are less likely to develop AS. 
4) specific dietary interventions improve symptoms of AS. 
 
Materials and methods 
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The review protocol was registered with PROSPERO (20), an international register of 
systematic reviews (registration number: CRD42015026699). We followed Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (21). 
Literature search strategy 
The search terms relating to AS (AS, Spondyloarthropathy, Spondylitis, spondyloarthritis) were 
combined with terms relating to diet (diet, nutrition, food, food habits, nutritional status, vitamins, 
antioxidants, fatty acids, carbohydrates, dietary protein, calcium, fish oils, fruit, vegetables, 
micronutrients) to find articles published up to August 2016 in Embase and Medline. Additionally, 
two journals (Annals of the Rheumatic Diseases and Annual Review of Nutrition) were searched 
manually from 2010 to 2015. The references of retrieved manuscripts were screened for further 
relevant papers. 
Inclusion and exclusion criteria 
We included all observational studies on humans (cross-sectional, cohort, case-control and 
case series studies) but we excluded case reports. We also excluded case series with small 
number of study participants (<5). Uncontrolled treatment outcome studies and Randomized 
controlled trials (RCT) were also included. Participants had to be at least 18 years old. We 
considered studies published in English that evaluated presence of AS (or axial spondyloarthritis 
(axSpA) using established criteria or clinical diagnosis, included assessment of diet and 
quantified an association between AS (or axSpA) and diet. In this review, we did not consider 
alcohol consumption. 
Data extraction 
Two independent reviewers screened the title and the abstract of each study following the 
inclusion criteria. If disagreement occurred between the two reviewers, a third reviewer was 
consulted.  
For eligible studies, data extraction was performed by two independent reviewers using a 
specially designed data collection form. 
Assessment of study quality 
We used the Scottish Intercollegiate Guidelines Network (SIGN) methodology checklists to 
assess the quality of individual studies (22). Two reviewers conducted the quality assessment 
independently. If disagreement occurred, a third reviewer was consulted. 
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The Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
approach was used to rate the quality of evidence (23,24). 
Results 
Search results 
The search of the databases resulted in 582 publications (Figure 1). After the removal of 
irrelevant papers (n=512) and duplicates (n=18) and having found additional 10 papers from 
other sources including searching the references of full text papers, 58 full text published papers, 
two letters and five conference abstracts were considered. After further consideration, three 
abstract were removed because they did not include the necessary information and 46 full text 
articles were removed because they did not report AS (n=3), did not look at relationship between 
AS and diet (n=2), included children (n=1), very small sample of AS patients (n= 4), contained 
case report (n=3), did not report information on diet (n=1), was in Chinese language (n=1), did 
not report diet (n=25), did not report information on AS (n=2), were non-systematic reviews (n=3) 
and thesis (duplicate publication, n=1). There were total of 16 studies included in the review, ten 
of which were full text papers (25,26,27,28,29,30,31,32,33,34), two were letters (35,36), two 
studies were summarised in review articles (37,38) and two were conference abstracts (39,40). 
Description of the included studies and participants 
Multiple studies were conducted in Sweden (27,32,33,34) and United Kingdom (37,38,28), and 
individual studies in Norway (25), Belgium (35), France (26), Australia (29), New Zealand (30), 
China (31), Portugal (39) and Turkey (40) (Table 1, Appendix 1) and were published between 
1991 (25) and 2014 (39,34,40). Seven of the included studies were case series 
(25,26,29,32,33,39,40); three were treatment outcome studies with all the participants receiving 
intervention (35,37,38), three were randomised clinical trials (27,28,30), one was case-control 
study (34) and one study investigated gene-environment interaction using a case-only design 
(31). All of the studies were conducted in hospital setting (Table 1, Appendix 1) except one (28) 
which recruited participant via a web site. Eight studies only reported inclusion criteria while 
three others only reported exclusion criteria. 
Participation rate was reported by three studies describing case series (25,29,32) (range 46%-
93%) and one case-control study (34) (89%). None of the treatment outcome studies reported 
follow-up rate, while follow up rate in RCTs was between 65% (28) and 100% (30). Minimum 
duration of follow up was 3 months and maximum 10 months (Table 1, Appendix 1).   
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Study size ranged from 12 (39) to 293 participants (26). Among 11 studies that reported gender 
distribution, females comprised between 19% (31) and 38% (27). Among 10 studies that 
reported age distribution, mean age ranged between 30 (31) and 50 (32) years. Only eight 
studies specified disease duration with mean ranging between 9 (30) and 27 (32) years (Table 
1, Appendix 2).  
Among nine studies that reported diagnostic criteria for AS the most common was Modified New 
York criteria (41) reported by five studies (29,31,32,33,34), the European Spondylarthropathy 
Study Group (ESSG) (42) reported by four studies (35,26,30,40), the Amor criteria (43) by two 
studies (26,40) and the Assessment of Spondyloarthritis International Society (ASAS) 
classification criteria (44) by one study (40) (Table 1, Appendix 2). 
The following criteria were used to measure disease activity: the Bath Ankylosing Disease 
Activity Index (BASDAI) (45) (9 studies), Bath Ankylosing Functional Index (BASFI) (46) (7 
studies), Bath AS Patient Global Score ( BASG) (47) (3 studies), AS Quality of Life (ASQoL) 
index (48) (2 studies), ASAS (49) and ASAS20 (50) (one study), SF-36 (51) (2 studies), 
erythrocyte sedimentation rate (ESR) (5 studies), C-reactive protein (CRP) (5 studies), 
aggravation of symptoms (25,32), change from baseline (35), VAS (36,30) and medication 
requirement (25,27) (Table 1, Appendix 2). 
Availability of information on diet and nutrition 
In the observational studies assessment of diet was conducted using questionnaire 
(25,31,32,33,34) with three studies (32,33,34) using a validated, 84-question semiquantitative 
food frequency questionnaire (FFQ) (52,53). Other methods used were food diary (39), face-to-
face interview (40), interview with a dietician (26) and telephone survey (29) (Table 1, Appendix 
2).  
Studies examined different types of food and nutrients in relation to AS, most commonly the 
consumption of starch, dairy and different types of diet (Table 2, 3, Appendix 3).  
Quality of studies 
As studies included in this systematic review had different designs, their quality was assessed 
separately as case series (Appendix 4), treatment outcome studies (Appendix 5), case-control 
study (Appendix 6) and RCTs (Appendix 7).  
The quality could not be fully assessed in studies published as abstracts (39,40), letters (35,36) 
or described in reviews (37,38). Overall GRADE quality of evidence was low or very low (Table 
2, 3) with only two studies, both RCTs, fully satisfying the quality criteria (28,30). In studies of 
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intervention, compliance was assessed by questioning the participants about adherence to diet 
(35,37), by counting the remaining capsules (27), by asking the participants to report on the 
number of study capsules that they had taken during the previous week (28) or by asking the 
participants to return all study drug containers for weighing (30).  
Most studies, especially more recent, used modern statistical methods and investigated the 
effects of potential confounding factors such as age, gender, smoking and body mass index (BMI) 
(Appendix 8). 
None of the studies investigated data to answer whether persons with particular diets are less 
likely to develop AS (Objective 3). 
Objective 1: Comparison of diet in patients with AS and those without AS 
Only one case-control study (34) investigated whether diet differs among AS patients compared 
to persons without AS (Table 2-3). The calculated energy intake was significantly higher among 
AS patients compared to controls (1,940 vs. 1,819 kcal, P<0.05). The difference in the calculated 
energy intake remained after adjustments for physical activity level, weight, sex and age. Apart 
from differences which were not significant, i.e. a lower intake of monounsaturated fats (P=0.07) 
and total fat (P=0.07) among the patients, there were no other differences in diet (consumption 
of dairy products, fish, meat, fruits and vegetables) compared with controls (Appendix 10-13).  
Ge et al (31) performed an association study examining gene-environment interaction between 
IL-1F7 gene polymorphisms and measures of dietary exposure. There was an interaction with 
type of cooking oil with an increased risk for cooking using half plants - half animal fats (OR 
4.27, 95% CI 1.59-11.48, P = 0.004). Interaction between IL-1F7 alleles and other factors such 
as salt, meat or vegetable consumption in AS patients was not statistically significant (all 
P>0.05) (Table 2-3; Appendix 12-14). 
Objective 2: Diet and severity of AS (observational studies) 
Overall, evidence on diet and AS severity was limited, and we were unable to perform a meta-
analysis due to lack of report of data, diversity in outcome and definition of exposure.  
Haugen et al (25) reported that 78% of AS patients believed that diet influenced symptoms of 
their disease and one third of the patients reported worsening symptoms after intake of certain 
foods with 35% mentioning increased swelling of the joints. Foods most frequently implicated 
were meat, coffee, sweets, sugar, chocolate, citrus fruits and apples. Sixteen percent of the AS 
patients had been through a fasting period on their own initiative with the majority reporting less 
pain, less stiffness and less joint swelling. Twenty-two percent of patients with AS in an attempt 
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to alleviate disease symptoms had previously tried diets such as lactovegetarian or vegan diets 
(Appendix 16).  
Of the four studies reporting data on the relationship between food high in starch and AS severity 
(26,32,39,40), two (26, 32) were conference abstracts (Appendix 9, Table 2). While one study 
(39) reported a significant association of daily starch intake with the BASDAI, BASFI and BASG, 
other studies did not find an association between consumption of food high in starch and 
BASDAI (26,40). There was no association of daily starch intake with the SF-36, CRP or ESR 
(39). A small proportion of patients (1.8%) reported aggravation of symptoms associated with 
food rich in flour (32). Silva (39) reported that average starch intake was significantly, positively 
associated with BASDAI, BASFI, and BASG but not with SF-36, CRP or ESR. The linear 
regression showed increases of 3%, 3.9% and 2.9% in BASDAI, BASFI and BASG scores, 
respectively, by milligram of ingested starch. The authors concluded that higher intake of starch 
was related to increased disease activity and greater functional impairment.  
Three studies that reported data on the relationship between consumption of dairy products and 
AS (32,26,40) did not find any association with BASDAI (Table 2, Appendix 10). One study that 
reported case series (32) did not find an association between consumption of fish and dietary 
omega-3 fatty and BASDAI (Table 2, Appendix 11). 
Sundström et al. (32) reported in a study of 111 patients that seven patients experienced 
aggravated arthralgia or AS symptoms associated with a particular foodstuff, most commonly 
vegetables/fruits (n=2) or food rich in flour (n=2) (Appendix 9, 12, Table 2).  
Taşpınar et al (40) reported no association between consumption of salt and fast food, and the 
BASDAI. Claudepierre et al (26) reported that among dietary factors the frequency of meals 
taken out of home was the only variable related (negatively) to disease activity. Mean (SD) 
BASDAI score among those eating out of home twice per week or less was 5.1 (2.1) compared 
to 4.1 (2.1) among those who ate out of home more than twice per week (P<0.001) (Table 2, 
Appendix 14). 
Sundström et al. (33) reported that there was no correlation between dietary fat intake and 
disease activity assessed by BASDAI. ESR correlated negatively with dietary total 
polyunsaturated fatty acids (PUFA) and omega-3 long-chain polyunsaturated fatty acids 
(LCPUFA) (rs = –0.25 and rs = –0.27, respectively, P<0.05). While no correlation between 
dietary intake and disease activity, as measured by BASDAI, was found overall Amongst 
women, there were negative correlations between the percentage energy intake derived from 
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fat and saturated fats with BASDAI (rs=−0.43, P<0.05 and rs=−0.50, P<0.01, respectively) (32) 
(Appendix 8, Table 3). 
Sundström et al. (32) stated that thirty-two patients (29%) reported that they had consumed 
herbal products, multivitamins and other food supplements during the preceding 2 weeks. The 
most common were omega-3 (n=13; median intake 1g/day), multivitamin and/or multimineral 
(n=12), and iron (n=4) supplements. (Table 2, Appendix 15). 
Chatfield et al (29) reported that 82.7% of AS patients used complementary and alternative 
medicine (CAM) and of these patients 16 (25.8%) were using seven or more types. Forty-four 
AS patients (72.1%) reported a form of dietary CAM among whom 28 (37.4%) were using 
multiple types at the time of study. The most common dietary CAMs were fish oil (26.7% of the 
study population), green tea (25.3%), vitamin supplements (24.0%) and glucosamine (21.3%). 
Of a total of 89 dietary CAM only 10 were initiated by a CAM practitioner and 50 were reported 
to be of little or no benefit. There was no significant difference between dietary CAM users and 
non-users across a range of disease indices (ESR, CRP, BASDAI, BASFI, ASQoL or BASG) 
(Table 2, Appendix 15). 
Objective 4: Dietary interventions and symptoms of AS 
Appelboom et al. (35) investigated, in a single-arm intervention study of 25 patients, whether a 
diet that excluded dairy products, was beneficial for the course of disease. The results at six 
weeks of follow up showed relatively good compliance to the diet (72%). Amongst participants, 
52% reported good improvement of whom 62% could discontinue their NSAID therapy. When 
follow up of the responders was carried out, 80% of 15 patients three months, all 10 patients at 
six months and 89% of 9 patients at nine months were satisfied and had continue the dietary 
regime. The authors reported that six patients were still observing the diet after two years of 
follow up and remained free from any other therapy (Table 2, Appendix 10). 
Ebringer and Wilson (37) in a single-arm intervention study of a low starch diet in 36 AS patients 
reported a significant reduction (P<0.001) in ESR levels over a 9-month period. The authors 
also reported that the majority of the participants reported that the severity of symptoms declined 
and in some cases disappeared. Some patients noticed a decrease in requirement for NSAIDs, 
however no precise figures were reported. The authors reported that they treated over 450 AS 
patients from 1983 onwards and that over half of these patients did not require any medication 
at follow up. Ebringer et al (38) reported a decrease in ESR in a single-arm intervention study 
of low starch, high protein, high vegetable and fruit diet with 10 months follow up, however 
precise figures were not reported (Table 2, Appendix 9). 
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Sundström et al (27) reported a randomised trial of high- versus low- dose fish oil with 21 weeks 
follow up with participants blinded to the dose. At the end of the study there was a statistically 
significant decrease in BASDAI scores (p=0.038) in the high-dose group and a statistically 
significant increase in ESR in the low-dose group (p=0.027), but no other significant differences. 
However, there was not a statistically significant difference comparing the high-dose and low-
dose groups (Table 2, Appendix 11). 
A small uncontrolled intervention study investigated the effects of giving Lactobacillus 
acidophilus and Lactobacillus salivarius daily for 4 weeks in 18 patients with quiescent ulcerative 
colitis but active SpA (36). Significant improvements were seen in BASDAI (reduction in mean 
(SD) from 5.8 (1.5) at baseline to 4 (1.8) at follow up, P<0.05) and pain VAS (reduction from 
58.1 (16.8) to 41.5 (14.3), P<0.05). However, neither of two RCTs found a significant effect of 
probiotic supplementation on AS outcome such as disease activity, function, wellbeing, 
BASDAI, BASFI, pain levels, CRP or ASQoL (28,30).  
We did not perform a meta-analysis due to diversity of outcomes and types of probiotic 
supplements (Table 2, Appendix 15). 
Discussion 
This is the first systematic review to examine the association between AS and diet. It has showed 
that only a few, relatively small, and mainly observational studies have been conducted in this 
field. From the 16 articles included in the review, there is little evidence that aspects of diet 
influence the severity of AS or are part of its aetiology. Specifically, there is no evidence that 
reduction in starch intake, exclusion of dairy products, fish and fish oil consumption and probiotic 
supplementation reduce susceptibility to AS or diminish AS symptoms. 
This review has many methodological limitations. Firstly, there is scarce literature on the topic and 
6 out of 16 studies were not published as full reports and therefore limited data were available for 
data extraction. Several studies did not report the actual figures and results of the analysis. The 
studies included in this review vary extensively in design, AS diagnostic criteria, measures of 
disease severity, exposure measured, measurement instruments, intervention and duration of 
follow-up. Therefore, it was not possible to conduct a meta-analysis. 
Although we limited our search to publications in English language, the studies included in this 
review were from ten countries. Most studies were conducted in hospital setting, except one study 
that used patient society website (28). The participation rate and way of selection the participants 
were not stated in the majority of the studies and therefore it is difficult to judge how representative 
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they were, limiting the generalizability of the findings. Most studies, especially more recent, used 
appropriate statistical methods and investigated the effects of potential confounding factors. 
Retrospective assessment of dietary exposure may introduce recall bias. However observational 
studies included in this review seem to evaluate current dietary habits, except one study (29) 
which collected information on special diets and food avoidance in the past three months and one 
study (39) that used food diary over the five consecutive days. In addition, when assessing dietary 
risk factors in prevalent cases of AS, it is difficult to distinguish whether diet influences the 
development of AS or the course of the disease. It is also common for people to change their diets 
soon after the onset of disease, and therefore current diet may not actually represent past dietary 
intake. Validated FFQ was used in three observational studies from the same research group 
(32,33,34), and reproducibility was assessed in study by Haugen et al (25), however reliability 
and validity of the dietary data collected in other studies was not clear.  
The majority of AS patients (78%) as well patients with other rheumatic diseases (rheumatoid 
arthritis (RA) 64%, juvenile rheumatoid arthritis (JRA) 88%, psoriatic arthropathy 71%, 
osteoarthrosis 65%) believe that diet influences their disease symptoms (25). This suggests that 
if diet is important it may influence the inflammatory process across rheumatic diseases.  
Studies of AS and other rheumatic diseases report dietary interventions such as fasting, vegan 
diet and lactovegetarian diet (25,54). Clinical dietary therapy studies of AS have focused on some 
form of dietary elimination such as low starch diet (37) and diet that excludes dairy products (35).  
Gut involvement in the pathogenesis of rheumatic diseases was proposed by Smith (55), and 
more recent studies investigated it further (54,56), suggesting that as the intestinal bacterial flora 
may be affected by diet, a diet which could influence the intestinal flora might have an effect on 
disease activity. Klebsiella pneumoniae was suggested as a trigger for AS and Crohn's disease 
based on molecular mimicry (12), and a low-starch diet was proposed as a means of reducing 
Klebsiella bacteria in the gut and hence further pathological damage (10,11,12,13). The gut 
microbiome can also be altered using probiotics, live bacteria and yeasts considered as having 
possible health benefits (57). Animal models have shown that Lactobacillus casei can reduce joint 
damage in mouse models of arthritis, while HLA-B27 transgenic rats have been shown to be less 
likely to have a relapse of colitis when given Lactobacillus rhamnosus GG (58). However while 
one uncontrolled study of probiotics (36) included in this review showed an improvement in 
BASDAI and VAS scores, two RCTs (28,30) did not confirm this association. Several small trials 
of probiotics in RA patients have reported marginal, non-significant beneficial effects (59,60,61) 
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on RA disease activity. A recent case-control study showed that breast feeding, which influences 
microbiota, reduces the risk of the development of AS (62). 
Core set of recommendations for patients with AS proposed by Feldtkeller et al (19) advises a 
reduction in meat consumption, and increase in consumption of fish and vegetarian meals. In 
addition, it is recommended that sufficient vitamin D and calcium intake are important to prevent 
osteoporosis. 
Conclusion 
In this systematic review, we have determined, from a relatively small number of studies, that the 
evidence on the relationship between diet and AS is extremely limited and we have highlighted 
important methodological weaknesses in the studies reviewed.  
Many AS patients believe that aspects of diet affect their symptoms and/or have altered their diets 
in attempt to improve symptoms. However, well-designed studies of dietary patterns and nutrients 
are required before any AS-specific recommendations could be made. Future prospective, 
population-based studies using validated dietary assessment methods should focus on dietary 
patterns that have been implicated in other inflammatory conditions, including cardiovascular 
disease, to determine whether diet plays a role in susceptibility to AS and AS severity.  
Clinical and Research Consequences 
• Information on relationship between diet and AS is extremely limited 
• Evidence on a possible relationship between AS and diet is inconclusive 
• There is need for large population-based epidemiological studies investigating the 
relationship between AS and diet 
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Figure legends 
 
Figure 1. Flow diagram of study selection process for the systematic review on diet and 
ankylosing spondylitis (AS) 
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            Table 1. Description of studies 
 
Description N or (min, max) as 
appropriate 
Total 16 
Publication year 1991, 2014 
Country 
Norway 
Belgium 
United Kingdom 
France 
Sweden 
Australia 
New Zealand 
China 
Portugal 
Turkey 
Italy 
 
1 
1 
3 
1 
4 
1 
1 
1 
1 
1 
1 
Study type 
Observational 
Case-control 
Case series 
 
Intervention 
Uncontrolled treatment outcome 
Randomised Clinical Trial (RCT) 
 
9 
1 
8 
 
6 
4 
3 
Study size 12, 439 
Gender 
% Females 
Not reported 
 
19, 56 
4 
Age (years) 
Not reported 
30,50 
5 
AS diagnostic criteria 
Modified New York 
European Spondylarthropathy Study Group (ESSG) 
Amor 
Assessment of Spondyloarthritis International Society (ASAS) 
Hospital diagnosis (not specified) 
 
5 
4 
2 
1 
7 
Measure of disease activity 
Bath Ankylosing Disease Activity Index (BASDAI) 
Bath Ankylosing Functional Index (BASFI) 
Bath AS Patient Global Score (BASG) 
AS Quality of Life (ASQoL) 
Assessment of Spondyloarthritis International Society (ASAS) 
36-Item Short Form Health Survey (SF-36) 
Erythrocyte Sedimentation Rate (ESR)  
C-reactive protein (CRP) 
Medication requirement 
Aggravation of symptoms 
Change from baseline 
Visual Analogue Scale (VAS) 
 
9 
7 
3 
2 
1 
2 
5 
5 
2 
1 
1 
1 
Assessment of diet 
Questionnaire 
Interview 
Telephone interview 
Food diary 
Intervention 
 
5 
2 
1 
1 
7 
 
AS ankylosing spondylitis;  
19 
 
Table 2. Summary of findings (type of food/diet) 
 
Exposure Outcome 
 
Food/ diet Patients with AS vs Controls Dietary consumption  
and severity of AS 
Dietary intervention 
and severity of AS 
Participants 
(studies) 
Result Quality of 
evidence 
(GRADE) 
Participants 
(studies) 
Result Quality of 
the 
evidence 
(GRADE) 
Participants 
(studies), 
follow-up 
Result Quality of 
evidence 
(GRADE) 
High-starch 
food 
- - - 405 (2) 
 
12 (1) 
 
12 (1) 
 
 
111 (1) 
-BASDAI: No 
association (no data) 
-ESR, CRP, SF-36: 
No association 
-BASDAI, BASFI, 
BASG: Sign. 
association 
-Symptom aggravation 
Very low 110 (2),  
9-10 
months 
 
36 (1), 9 
months 
Low starch diet: 
Sign. Reduction 
in ESR 
Symptom 
improvement (no 
data) 
Very Low  
Dairy products 77 AS / 
307 
Controls (1) 
No sign. 
difference 
Low 504 (3) BASDAI: No 
association (no data) 
Very low 25 (1), 9 
months 
Dairy excl. diet: 
Self-reported 
therapeutic effect 
Very Low 
Fish / fish oil 77 AS /307 
Controls (1) 
Fish 
consumption: 
No sign. 
difference 
Low 111 (1) Fish consumption: No 
association (no data) 
Very low 18 (1), 21 
weeks 
High- vs low-dose 
fish oil: No sign. 
difference 
Very Low 
Meat and 
meat products 
77 AS /307 
Controls (1) 
150 AS 
only (1) 
-No sign. 
difference 
- Non-sign. 
gene IL-1F7 
interaction 
Low 404 (2) BASDAI: No 
association (no data) 
Very low - - - 
Fruit and 
vegetables 
77 AS /307 
Controls (1) 
150 AS 
only (1) 
-No sign. 
difference 
- Non-sign. 
gene IL-1F7 
interaction 
Low 111 (1) Symptom aggravation Very low - - - 
Probiotic 
supplements 
- - - - - - 18 (1), 4 
weeks 
 
 
 
-BASDAI, VAS: 
Sign. association 
- BASFI, ESR, 
CRP: No 
association 
Low 
20 
 
 
196 (2), 12 
weeks 
BASDAI, VAS, 
BASFI, CRP, 
ASQoL: No sign. 
difference 
compared to 
placebo 
CAM - - - 75 (1) BASDAI, BASFI, 
BASG, ASQoL, ESR, 
CRP: No association 
Very Low - - - 
Cooking oil 150 AS 
only (1) 
Sign. gene IL-
1F7 interaction 
(half plants-
half animal fat) 
Low - - - - - - 
Salt 
consumption 
150 AS 
only (1) 
Non-sign. 
gene IL-1F7 
interaction 
Low 100 (1) BASDAI: No 
association (no data) 
Very Low - - - 
Convenience 
food 
- - - 293 (1) 
 
 
 
 
 
 
 
100 (1) 
BASDAI: No 
association with 
consumption of 
canned or frozen food 
(no data); Sign. 
inverse association 
with number of meals 
taken out of home 
BASDAI: No 
association with fast 
food consumption (no 
data) 
Very Low - - - 
 
AS: ankylosing spondylitis; BASDAI: Bath Ankylosing Disease Activity Index; ASQoL: AS Quality of Life; ESR: Erythrocyte Sedimentation Rate; CRP: 
C-reactive protein; SF-36: 36-Item Short Form Health Survey; -BASDAI: Bath Ankylosing Disease Activity Index; BASFI: Bath Ankylosing Functional 
Index; BASG: Bath AS Patient Global Score; VAS: Visual Analogue Scale; GRADE: Grading of Recommendations Assessment, Development and 
Evaluation system 
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Table 3. Summary of findings (nutrients) 
Exposure Outcome 
Nutrient Patients with AS vs Controls Dietary consumption  
and severity of AS 
Participants 
(studies) 
Result Quality of 
evidence 
(GRADE) 
Participants 
(studies) 
Result Quality of evidence 
(GRADE) 
Energy 77 AS /307 
Controls (1) 
Sign. higher in 
cases 
Low 111 (1) BASDAI: No association (no data) Very Low 
Protein 77 AS /307 
Controls (1) 
No sign. 
difference 
Low 177 (2) BASDAI, ESR, CRP: No 
association  
Very Low 
Carbohydrate 77 AS /307 
Controls (1) 
No sign. 
difference 
Low 177 (2) BASDAI, ESR, CRP: No 
association 
Very Low 
Fat 77 AS /307 
Controls (1) 
No sign. 
difference 
Low 111 (1) 
 
 
66 (1) 
BASDAI: Sign association in 
women only 
BASDAI, ESR, CRP: No 
association 
Very Low 
Fibre 77 AS /307 
Controls (1) 
No sign. 
difference 
Low 111 (1) BASDAI: No association (no data) Very Low 
Saturated fatty 
acids 
77 AS /307 
Controls (1) 
No sign. 
difference 
Low 177 (2) BASDAI, ESR, CRP: No 
association 
Very Low 
Mono-unsaturated 
fatty acids 
77 AS /307 
Controls (1) 
No sign. 
difference 
Low - - - 
Poly-unsaturated 
fatty acids 
77 AS /307 
Controls (1) 
No sign. 
difference 
Low 177 (2) 
 
66 (1) 
BASDAI, CRP: No association 
ESR: Sign. association 
Very Low 
Linoleic acid 77 AS /307 
Controls (1) 
No sign. 
difference 
Low 66 (1) BASDAI, ESR, CRP: No 
association 
Very Low 
Alpha-linolenic acid 77 AS /307 
Controls (1) 
No sign. 
difference 
Low 66 (1) BASDAI, ESR, CRP: No 
association 
Very Low 
Long-chain omega-
3 fatty acids 
77 AS /307 
Controls (1) 
No sign. 
difference 
Low 177 (2) 
 
66 (1) 
BASDAI, CRP: No association 
 
ESR: Sign. association 
Very Low 
 
AS: ankylosing spondylitis; BASDAI: Bath Ankylosing Disease Activity Index; ESR: Erythrocyte Sedimentation Rate; CRP: C-reactive protein; 
GRADE: Grading of Recommendations Assessment, Development and Evaluation system 
  
22 
 
 
List of Appendices (For online publication) 
 
Appendix 1. Description of the included studies 
Appendix 2. Description of participants 
Appendix 3. Availability of dietary information in the studies included in the review 
Appendix 4. Quality assessment of studies reporting case series 
Appendix 5. Quality assessment of uncontrolled treatment outcome studies 
Appendix 6. Quality assessment of case-control studies 
Appendix 7. Quality assessment of RCTs 
Appendix 8. Methods used for statistical data analysis 
Appendix 9. Summary of evidence on relationship between high-starch food and AS 
Appendix 10. Summary of evidence on relationship between dairy products and AS 
Appendix 11. Summary of evidence on relationship between consumption of fish and fish oil 
and AS 
Appendix 12. Summary of evidence on relationship between consumption of fruit and 
vegetables and AS 
Appendix 13. Summary of evidence on relationship between consumption of meat and meat 
products and AS 
Appendix 14. Summary of evidence on relationship between consumption of convenience 
food, cooking oil and salt and AS 
Appendix 15. Summary of evidence on relationship between probiotic and other CAM 
supplementation and AS 
Appendix 16. Summary of evidence on relationship between specific diet and AS 
Appendix 17. Summary of evidence on relationship between nutrient intake and AS 
Appendix 18. Summary of evidence on relationship between dietary fatty acids intake and AS 
 
23 
 
 
Appendix 1. Description of the included studies 
First author, 
Publication 
year 
Country Study type Recruitment Inclusion criteria Exclusion criteria Follow 
up 
(months) 
Particip. 
rate 
Haugen, 1991 
(25) 
Norway Case series Oslo Sanitetsforening 
Rheumatism Hospital and 
Department of 
Rheumatology, University 
Hospital of Tromsø 
Age above 18 years No information N/A 46% 
Appelboom, 
1994 (35) 
Belgium Uncontrolled 
treatment 
outcome 
Outpatient clinic No information No information 9 No 
information 
Ebringer, 1996 
(37) 
United 
Kingdom 
Uncontrolled 
treatment 
outcome 
Middlesex Hospital, London Active AS (ESR>15 mm/hr) No information 9 No 
information 
Claudepierre, 
1998 (26) 
France Case series Nine rheumatology 
departments throughout 
France 
No information No information N/A No 
information 
Ebringer, 2006 
(38) 
United 
Kingdom 
Uncontrolled 
treatment 
outcome 
AS research clinic, Middlesex 
Hospital, London 
No information No information 10 No 
information 
Sundström, 
2006 (27) 
Sweden RCT Hospitals of Gällivare and 
Kiruna 
Active disease, age 18-70 years, 
having diagnosis of AS made by 
a rheumatologist 
Treatment with 
methotrexate, etanercept or 
infliximab, pregnancy, 
active Crohn's disease, 
food intolerance to fish 
5.3 Follow up 
rate 75%  
Brophy 2008 
(28) 
United 
Kingdom 
RCT Internet link posted on NASS 
website 
Age above 18 years, resident in 
UK, access to internet, 
diagnosis of SpA 
Immunosuppressive 
disorder 
3 Follow up 
rate 65% 
Chatfield, 
2009 (29) 
Australia Case series Austin Spondylitis Clinic (AS 
referral centre), Melbourne 
Satisfy modified New York 
criteria for AS 
No information N/A 92.6% 
Sanges, 2009 
(36) 
Italy Uncontrolled 
treatment 
outcome 
Gastroenterology unit, 
Naples 
Active SpA (BASDAI≥4), and 
quiescent ulcerative colitis 
according to UCDAI 
No information 4 weeks No 
information 
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Jenks 2010 
(30) 
New 
Zealand 
RCT Department of 
Rheumatology, Dunedin 
Hospital 
BASDAI≥3, BASFI≥3, MASES≥2 
or peripheral joint count ≥2 
Pregnancy, age<18 years, 
diagnosis IBD, severe 
immunosuppression, or 
current gastrointestinal 
infection 
3 Follow up 
rate 100% 
Ge, 2011 (31) China Cases-only G 
x E interaction 
Department of 
Rheumatology, First Affiliated 
Hospital, Anhui Medical 
University 
No information No information N/A No 
information 
Sundström, 
2011 (32) 
Sweden Case series Department of 
Rheumatology, County of 
Västerbotten 
Patients with a registered ICD-
10 M45.9 diagnosis of AS 
No information N/A 83% 
Sundström, 
2012 (33) 
Sweden Case series Department of 
Rheumatology, University 
Hospital of Umeå 
Patients diagnosed with AS and 
fulfilling the modified New York 
criteria, age 18–70 years 
Pregnancy, lactation, use of 
lipid-lowering medication, 
treatment with dalteparin 
sodium, warfarin, or 
biological products 
N/A No 
information 
Silva, 2014 
(39) 
Portugal Case series Rheumatology Department of 
Centro Hospitalar de Lisboa 
Ocidental, Hospital de Egas 
Moniz 
No information No information N/A No 
information 
Sundström, 
2014 (34) 
Sweden Case-control Cases: Department of 
Rheumatology, County of 
Västerbotten 
Controls: VIP database 
Cases: Patients diagnosed with 
AS and fulfilling the modified 
New York criteria, age 18–70 
years 
Controls: Matched for age (±2.5 
years), gender and date in VIP 
database 
No information N/A 89% 
Taşpınar, 
2014 (40) 
Turkey Case series Department of Rheumatology 
and Department of Physical 
Medicine and Rehabilitation, 
Bezmiâlem Vakif University, 
Istanbul 
No information No information N/A No 
information 
 
AS: ankylosing spondylitis; RCT: Randomised clinical trial; BASDAI: Bath Ankylosing Disease Activity Index; ESR: Erythrocyte Sedimentation Rate; 
UCDAI: Ulcerative Colitis Disease Activity Index ; N/A: Not applicable; BASFI: Bath Ankylosing Functional Index; VIP: Västerbotten Intervention 
Programme; G x E: Gene x Environment interaction; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; ICD-10: International Classification 
of Diseases, Tenth Revision; NASS: National Ankylosing Spondylitis Society; 
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Appendix 2. Description of participants 
First author, 
Publication year 
Study 
size 
Females,  
n (%) 
Age, years Disease duration, 
years 
AS Diagnostic criteria Assessment of 
diet 
Measure of 
disease activity 
Haugen, 1991 
(25) 
87 30 (34%) Median 36 
(Range 18-62) 
Median 9 
(Range 0-35) 
Hospital diagnosis Questionnaire 
(influence of diet on 
symptoms; 
reproducibility 
assessed) 
Aggravation of 
symptoms (0-10cm 
VAS); NSAIDs 
/corticosteroids 
intake 
Appelboom, 1994 
(35) 
25 No 
information 
No information No information ESSG Intervention Change in 
comparison to 
baseline (worse, no 
change, better) 
Ebringer, 1996 
(37) 
36 No 
information 
No information No information Hospital diagnosis Intervention ESR 
Claudepierre, 
1998 (26) 
293 107 (36.5) Mean 40.3  
(SD 13.5) 
Mean 10.7  
(SD 9.9) 
ESSG or Amor  Interview with a 
dietician 
BASDAI 
Ebringer, 2006 
(38) 
74 No 
information 
No information No information Hospital diagnosis Intervention ESR 
Sundström, 2006 
(27) 
24 9 (37.5) Median 49 
(Range 33-69) 
Median 19  
(IQR 15) 
Diagnosis of AS by a 
rheumatologist 
Intervention ESR, BASDAI, 
BASFI, analgesics 
and NSAIDs intake 
Brophy 2008 (28) 147 40 (30%) Pl Mean 42.7 (SD 
12.7) 
Pr Mean 44.8 (SD 
12.1) 
Pl Mean 20.3  
(SD 13.4) 
Pr Mean 20.3  
(SD 13.2) 
Diagnosis of SpA made 
by a rheumatologist and 
confirmed by x-ray or 
magnetic resonance 
scan 
Intervention Global wellbeing (0-
10), disease activity 
(0-10), function (0-
10); 10=the worst 
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Chatfield, 2009 
(29) 
75 24 (32.0) Mean 48.2  
(SD 12.9) 
Mean 21.8 
(SD 12.2) 
Modified New York Telephone survey 
(open-ended 
questions on 
avoidance of foods, 
special diets, CAM 
in the past 3 
months 
BASDAI, BASFI, 
ASQoL, BASG, 
ESR, CRP 
Sanges, 2009 
(36) 
18 10 (56%) Mean 49 No information Hospital diagnosis Intervention BASFI, BASDAI, 
VAS, CRP, ESR 
Jenks 2010 (30) 63 23 (37%) Mean 43.3 
(range 19-76) 
Mean 8.9 
(range 1-53) 
ESSG Intervention BASFI, BASDAI, 
ASAS, ASAS20, 
CRP, fatigue, 
global assessment 
VAS, ASQoL 
Ge, 2011 (31) 150 28 (19%) Mean 29.9  
(SD 9.61) 
No information Modified New York Questionnaire 
(yes/no questions) 
N/A 
Sundström, 2011 
(32) 
111 27 (24%) Mean 49.5  
(SD 10.4) 
Mean 26.9  
(SD 10.5) 
Modified New York Questionnaire 
(validated) 
BASDAI, BASFI, 
Aggravation of 
symptoms 
Sundström, 2012 
(33) 
66 15 (22.7) Mean 47.7  
(SD 10.0) 
Mean 17.0  
(SD 10.8) 
Modified New York Questionnaire 
(validated) 
BASDAI, BASFI, 
BASG, SF-36, CRP 
Silva, 2014 (39) 12 3 (25%) No information No information No information Food diary 
(5 consecutive 
days) 
BASDAI, BASFI, 
BASG, SF-36, 
CRP, ESR 
Sundström, 2014 
(34) 
88 
351 
20 (23%) Cases: Median 50 
(Range 40-60) 
No information Modified New York Questionnaire 
(validated) 
N/A 
Taşpınar, 2014 
(40) 
100 No 
information 
No information No information ESSG, ASAS, Amor Interview BASDAI 
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VAS: Visual Analogue Scale; ESSG: European Spondylarthropathy Study Group; NSAIDs: nonsteroidal anti-inflammatory drugs; ESR: 
Erythrocyte Sedimentation Rate; BASDAI: Bath Ankylosing Disease Activity Index; BASFI: Bath Ankylosing Functional Index; SpA: 
Spondyloarthritis; CAM: Complementary and alternative medicines; Pr: Probiotics; Pl: Placebo; ASQoL: AS Quality of Life; CRP: C-reactive 
protein; BASG: Bath AS Patient Global Score; ASAS : Assessment of Spondyloarthritis International Society; SF-36: 36-Item Short Form Health 
Survey; AS: ankylosing spondylitis; 
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Appendix 3. Availability of dietary information in the studies included in the review 
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 Diet 
Dairy                 5 
Foods high in starch                 6 
Fish                 2 
Fruit and vegetables                 3 
Meat and meat products                 4 
Cooking oil                 1 
Salt consumption                 2 
Canned food                 1 
Frozen foods                 1 
Fast food                 1 
Meals taken out of home                 1 
Believe that diet influences 
symptoms 
                1 
Foods that aggravate 
symptoms 
                2 
Fasting                 1 
Specific diet                 1 
 Nutrients 
Energy                 3 
Fat                 3 
Protein                 3 
Starch                 1 
Carbohydrate                 2 
Fatty acids                 2 
Fibre                 2 
 Dietary complementary and alternative medicines (CAM) 
Probiotics                 3 
Fish oil                 3 
Other CAM                 2 
CAM: Complementary and alternative medicines;  
29 
 
Appendix 4. Quality assessment of studies reporting case series 
 
 
Criteria First author, publication year 
Haugen, 
1991 (25) 
Claudepierre, 
1998 (26) 
Chatfield, 
2009 (29) 
Ge, 2011 
(31) 
Sundström, 
2011 (32) 
Sundström, 
2012 (33) 
Silva, 
2014 
(39) 
Taşpınar, 
2014 (40) 
State specific objectives, including any pre-
specified hypotheses 
Yes Not clear  Yes Yes Yes Yes Yes Yes 
Study population is clearly and fully 
described, including a case definition, 
inclusion and exclusion criteria    
No Yes Yes Yes Yes Yes Yes Can’t tell 
Were the cases consecutive?     Yes Yes Can’t tell No Can’t tell Can’t tell Can’t 
tell 
Can’t tell 
The sample of cases is representative with 
regard to the population to which the findings 
are be referred 
Can’t tell Can’t tell No Can’t tell Can’t tell Can’t tell No Can’t tell 
The sample size is based on pre-study 
considerations of statistical power 
Can’t tell No Can’t tell No No No Can’t 
tell 
Can’t tell 
Participation rate is reported Yes Yes No Yes Yes No No No 
The outcome measures are clearly defined, 
valid, reliable, and implemented consistently 
across all study participants 
Yes Yes No Yes Yes Yes Yes Yes 
The exposure measurements (e.g. 
questionnaires) are likely to be valid and 
reliable? 
Yes Yes Yes Yes Yes Yes Yes Yes 
Confidence intervals are provided No No Yes Yes No No No No 
The potential confounders are identified and 
taken into account in the design and 
analysis. 
No No No No No No Yes No 
Laboratory methods are described, including 
source and storage of DNA, genotyping 
methods and platforms, error rates ad call 
rates. 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Yes Not 
applicable 
Not 
applicable 
Not 
applic
able 
Not 
applicable 
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Appendix 5. Quality assessment of uncontrolled treatment outcome studies 
 
Criteria 
First author, publication year 
Appelboom, 
1994 (35) 
Ebringer, 
1996 (37) 
Ebringer, 
2006 
(38) 
Sanges, 
2009 (36) 
State specific objectives, including any pre-
specified hypotheses 
Yes No No Yes 
The study population is clearly and fully 
described, including a case definition, 
inclusion and exclusion criteria 
Yes No No No 
The sample size was based on pre-study 
considerations of statistical power 
Can’t tell Can’t tell No Can’t tell 
The baseline participation rate is 
reported 
No No No No 
The follow up (or dropout) rate is 
reported 
No No No No 
Comparison is made between full 
participants and those lost to follow up 
No No No No 
The outcome measures are clearly 
defined, valid, reliable, and implemented 
consistently across all study participants 
Yes Yes No Yes 
Confidence intervals are provided No No No No 
The potential confounders are identified 
and taken into account in the design and 
analysis. 
Yes No No No 
Compliance assessment Questions to 
participants 
(poor, 
questionable, 
good) 
Self-report 
(minority of 
patients 
reported 
difficulty to 
adhere to 
diet; 
support 
was 
available) 
Can’t tell Can’t tell 
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Appendix 6. Quality assessment of case-control studies 
 
 
Criteria 
First author, 
publication year 
Sundström, 2014 
(34) 
State specific objectives, including any pre-specified hypotheses Yes 
The case population is clearly and fully described, including a case definition, 
inclusion and exclusion criteria 
Yes 
Cases are clearly differentiated from controls. 
Yes 
Sample size is based on pre-study considerations of statistical power? No 
The cases and controls are taken from comparable populations Yes 
The same exclusion criteria are used for both cases and controls Yes 
Participation rate for both cases and controls is reported 
No (cases only) 
Comparison is made between participants and non-participants to establish 
their similarities or differences. 
Yes 
Measures will have been taken to prevent knowledge of primary exposure 
influencing case ascertainment 
Not mentioned 
Exposure status is measured in a standard, valid and reliable way 
Yes 
The main potential confounders are identified and taken into account  in the 
design and analysis 
Yes 
Confidence intervals are provided 
No 
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Appendix 7. Quality assessment of randomised clinical trials (RCTs) 
 
 
Criteria 
First author, publication year 
Sundström, 2006 
(27) 
Brophy 2008 
(28) 
Jenks 2010 
(30) 
State specific objectives, including any pre-specified hypotheses Yes Yes Yes 
The study population is clearly and fully described, including a case definition, 
inclusion and exclusion criteria 
Yes Yes Yes 
The sample size is based on pre-study considerations of statistical power No Yes Yes 
The assignment of subjects to treatment groups is random Yes Yes Yes 
An adequate concealment method was used Can’t tell Yes Yes 
The design keeps subjects and investigators ‘blind’ about treatment allocation Can’t tell Yes Yes 
The treatment and control groups are similar at the start of the trial Yes Yes Yes 
The follow up (or dropout) rate is reported Yes Yes Yes 
The outcome measures are clearly defined, valid, reliable, and implemented 
consistently across all study participants  
Yes Yes Yes 
Intention to treat analysis was conducted No Yes Yes 
Confidence intervals are provided No Yes Yes 
Compliance assessment Participants 
counted the 
remaining 
capsules 
Participants 
reported on the 
number of study 
capsules that 
they had taken 
during the 
previous week 
Participants 
returned all 
study drug 
containers at 
weeks 4, 8 and 
12; Containers 
were weighted 
to document 
compliance 
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Appendix 8. Methods used for statistical data analysis 
 
First author, 
Publication year 
Statistical methods used Confounding factors considered 
Haugen, 1991 
(25) 
Percent;  
 
Information was available on age, gender 
and disease duration but no report on 
relationship with disease symptoms 
Appelboom, 1994 
(35) 
Percent; Fisher's exact test; Chi-square 
test  
No association between response and age, 
gender, duration of disease, HLA-B27, axial 
versus peripheral involvement, 
enthesopathies, sacroiliitis, intestinal, 
genitourinary or cutaneous symptoms. 
Ebringer, 1996 
(37) 
Mean; SE; t-test No information 
Claudepierre, 
1998 (26) 
Mean; SD; Median; rage; correlation; 
Kruskall-Wallis test; Mann-Whitney U 
test; Linear regression 
Age at disease onset, gender, HLA-B27 
status, disease duration 
Ebringer, 2006 
(38) 
No information No information 
Sundström, 2006 
(27) 
Median; IQR; Mann-Whitney U test; 
Fisher exact test; Wilcoxon signed rank 
test 
RCT (baseline information was collected on 
age, gender, age at onset of symptoms, 
disease duration, time to diagnosis) 
Brophy 2008 (28) Percent; Mean; SD; General linear 
model adjusted or age, gender, disease 
duration and baseline levels 
RCT (baseline information was collected on 
age, gender, disease duration, iritis, 
inflammatory bowel disease, medication) 
Chatfield, 2009 
(29) 
Mean; SD; Percent; t-test; chi-square 
test; Multivariate logistic regression 
Age, gender, HLA-B27 status, disease 
duration, delay in diagnosis, family history, 
peripheral arthritis, smoking, education, 
employment, medication 
Sanges, 2009 
(36) 
Mean; SD; t-test Age, gender 
Jenks 2010 (30) Mean; SD; Percent; ANCOVA RCT (baseline information was collected on 
age, gender, disease duration, HLA-B27 
status, history of anterior uveitis, history of 
psoriasis, medication) 
Ge, 2011 (31) OR; 95% CI; Logistic regression; P-
value for interaction 
Information was available on age, gender, 
HLA-B27 (all positive), smoking, medical 
history 
Sundström, 2011 
(32) 
Percent; Mean; SD; Mann-Whitney U 
test; Fisher exact test; Spearman’s rank 
correlation; multiple logistic regression 
Age, gender, disease duration, BMI, 
physical activity 
Sundström, 2012 
(33) 
Percent; Mean; SD; Mann-Whitney U 
test; Fisher exact test; Spearman’s rank 
correlation; Pearson correlation; multiple 
linear regression 
Age, gender, disease duration, BMI, 
physical activity, smoking 
Silva, 2014 (39) Mean; SD; Pearson correlation; Linear 
regression 
Age, gender, medication, BMI 
Sundström, 2014 
(34) 
Spearman’s rank correlation; conditional 
logistic regression; multiple linear 
regression 
Age, gender, BMI, physical activity, 
education, smoking; medication; medical 
history 
Taşpınar, 2014 
(40) 
Correlation Age, gender, disease duration, smoking, 
medical history 
 
SD: Standard deviation; SE: Standard error; OR: Odds ratio; CI: Confidence interval; ANCOVA: 
Analysis of covariance; IQR: Interquartile range; HLA-B27: human leukocyte antigen B27; BMI: Body 
mass index 
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Appendix 9. Summary of evidence on relationship between high-starch food and AS 
 
First 
author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants
(duration of 
follow up) 
Exposure Outcomes Results/Conclusion 
Ebringer 
1996 (37) 
Summary in 
review 
paper 
Uncontrolled 
treatment 
outcome 
36 
(9 months) 
Low starch diet 
(reduced intake of 
bread, potatoes, chips, 
rice, spaghetti, cereals, 
cakes, biscuits) 
ESR, symptom 
severity, 
requirement 
for NSAIDs 
- Significant reduction in ESR levels from mean (SE) of 38 
(3) mm/hr at baseline to 24 (2) mm/hr at follow up 
(P<0.001) 
- Majority of the participants reported that the severity of 
symptoms declined and in some cases disappeared (no 
precise figures were reported).  
- Some patients noticed decrease in requirement for 
NSAIDs (no precise figures were reported) 
Ebringer 
2006 (38) 
Summary in 
review 
paper 
Uncontrolled 
treatment 
outcome 
74 
(10 months) 
Low starch, high 
protein, high vegetable 
and fruit diet 
ESR Decrease in ESR (no precise figures were reported) 
Claudepierre 
1998 (26) 
Full text Case series 293 Consumption of food 
high in starch content 
(i.e. bread, pasta, rice, 
potatoes, rusk, maize, 
beans, peas, pizza, 
quiches, couscous) 
Weekly starch 
consumption 
BASDAI No association (no precise figures were reported) 
Sundström 
2011 (32) 
Full text Case series 111 Food rich in flour Aggravated 
arthralgia or 
AS symptoms 
2 (1.8%) patients reported that they experienced 
aggravation of symptoms associated with food rich in flour 
Silva 2014 
(39) 
Conference 
abstract 
Case series 12 Average daily starch 
intake 
BASDAI, 
BASFI, BASG, 
SF-36, CRP, 
ESR 
- Significant association with the BASDAI (p<0.05), BASFI 
(p<0.05), and BASG (p<0.05); The liner regression 
showed an increase of 3%, 3.9% and 2.9% in BASDAI, 
BASFI and BASG scores, respectively, by milligram of 
ingested starch 
- No association with the SF-36, CRP or ESR (no precise 
figures were reported)  
Taşpınar 
2014 (40) 
Conference 
abstract 
Case series 100 Consumption of wheat, 
cereal, whole wheat 
bread, white bread 
BASDAI No association (p>0.05) (no precise figures were 
reported) 
35 
 
AS: ankylosing spondylitis; ESR: Erythrocyte Sedimentation Rate; NSAIDs: nonsteroidal anti-inflammatory drugs; SE: Standard error; BASDAI: Bath 
Ankylosing Disease Activity Index; BASFI: Bath Ankylosing Functional Index; BASG: Bath AS Patient Global Score; SF-36: 36-Item Short Form 
Health Survey; CRP: C-reactive protein; 
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Appendix 10. Summary of evidence on relationship between dairy products and AS 
 
First 
author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants
(duration of 
follow up) 
Exposure Outcomes Results/Conclusion 
Appelboom 
1994 (35) 
Letter Uncontrolled 
treatment 
outcome 
25 
(9 months) 
Diet that excluded 
dairy products 
(milk, cheese, 
yoghurt, ice cream 
and butter), 
Self-reported 
therapeutic effect,  
NSAID therapy 
- 52% reported good and 16% a moderate improvement at 
6 weeks follow up. 
- 62% of 13 “good” responders could discontinue NSAID 
therapy at 6 weeks follow up. 
- 80% of 15 patients were still satisfied and kept up the 
diet at 3 months,  
- 100% of 10 patients were still satisfied and kept up the 
diet at 6 months  
- 89% of 9 patients were still satisfied and kept up the diet 
at 9 months.  
Sundström 
2014 (34) 
Full text Case-
control 
77 AS 
307 Controls 
Milk and soured 
milk 
AS No significant difference between cases and controls. 
Median (IQR) serving per week in AS cases: 13 (7.5-
18.1), controls: 11 (7.0-18.7) (P=0.61). 
Sundström 
2011 (32) 
Full text Case series 111 Milk and soured 
milk 
BASDAI No correlation (no precise figures were reported) 
Claudepierre 
1998 (26) 
Full text Case series 293 Dairy BASDAI No association (no precise figures were reported) 
Taşpınar 
2014 (40) 
Conference 
abstract 
Case series 100 Consumption of 
milk, yogurt, 
cheese, butter, 
margarine 
BASDAI No association (p>0.05) (no precise figures were 
reported) 
 
AS: ankylosing spondylitis; IQR: Interquartile range; BASDAI: Bath Ankylosing Disease Activity Index; NSAIDs: nonsteroidal anti-inflammatory drugs; 
 
  
37 
 
 
Appendix 11. Summary of evidence on relationship between consumption of fish and fish oil and AS 
 
 
First 
author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants 
(duration of 
follow up) 
Exposure Outcomes Results/Conclusion 
Sundström 
2006 (27) 
Full text RCT 24 (baseline);  
18 (follow up) 
(21 weeks) 
High- versus low- 
dose fish oil 
BASDAI, BASFI, 
ESR, medication 
requirement 
No statistically significant difference; a trend towards a 
larger decrease from baseline in BASDAI was seen in the 
high-dose group (estimated from publication mean 1.4) 
compared to low-dose group (mean 0.57) (p=0.145); 
Trend towards decreased symptoms in the high-dose 
group according to patients’ assessment of the effect of 
supplementation (P=0.102) 
Sundström 
2011 (32) 
Full text Case 
series 
111 Fish consumption, 
use of omega-3 
supplements in the 
past 2 weeks, 
omega-3 fatty acids 
as % of energy 
intake 
BASDAI No correlation (no precise figures were reported); 
13 (12%) used pmega-3 supplements (median intake 
1g/day, range 0.5-6.0) 
Sundström 
2014 (34) 
Full text Case-
control 
77 AS 
307 Controls 
Fish consumption AS No significant difference between cases and controls. 
Median (IQR) serving per week in AS cases: 1.6 (1.0-2.1), 
controls: 1.6 (0.6-2.1) (P=0.49). 
 
AS: ankylosing spondylitis; IQR: Interquartile range; BASDAI: Bath Ankylosing Disease Activity Index; BASFI: Bath Ankylosing Functional Index; 
ESR: Erythrocyte Sedimentation Rate; 
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Appendix 12. Summary of evidence on relationship between consumption of fruit and vegetables and AS 
 
First 
author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants  
Exposure Outcomes Results/Conclusion 
Ge 2011 
(31) 
Full text Case 
series 
 
150 Current vegetable 
consumption 
(frequency) 
AS OR (95% CI) for interaction between IL-1F7 gene 
(rs3811047) and vegetable consumption 
(Reference category: Less than six times per week) 
Once per day 0.311 (0.063–1.533) P=0.151 
2–3 times per day 0.375 (0.079–1.778) P=0.217 
More than three times per day 0.067 (0.004–1.116) 
P=0.060 
Sundström 
2011 (32) 
Full text Case 
series 
 
111 Vegetables and 
fruits (servings per 
month) 
Aggravated 
arthralgia or AS 
symptoms 
2 (1.8%) patients reported that they experienced 
aggravation of symptoms associated with vegetables/fruits 
Sundström 
2014 (34) 
Full text Case-
control 
77 AS 
307 Controls 
Vegetables and 
fruits (servings per 
week) 
AS No significant difference between cases and controls.  
Median (IQR) serving of vegetables per week in AS 
cases: 7.6 (6.0-14.4), controls: 7.6 (4.5-14.7) (P=0.57); 
 
Median (IQR) serving of fruits per week in AS cases: 8.0 
(4.1-14.0), controls: 7.6 (3.6-12.9) (P=0.80) 
 
AS: ankylosing spondylitis ; OR: Odds ratio; CI: Confidence interval; IQR: Interquartile range;  
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Appendix 13. Summary of evidence on relationship between consumption of meat and meat products and AS 
 
First 
author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants  
Exposure Outcomes Results/Conclusion 
Claudepierre 
1998 (26) 
Full text Case 
series 
293 Consumption of 
delicatessen food 
 
BASDAI No association (no precise figures were reported) 
Ge 2011 
(31) 
Full text Case 
series 
 
150 Meat products 
consumption (type) 
AS OR (95% CI) for interaction between IL-1F7 gene 
(rs3811047) and meat products consumption (reference 
category: Fat) 
Fat and lean 1.793 (0.182–17.651) P=0.617 
Lean 1.351 (0.144–12.636) P=0.792 
Sundström 
2011 (32) 
Full text Case 
series 
 
111 Meat and meat 
products (servings 
per month) 
BASDAI No correlation (no precise figures were reported) 
Sundström 
2014 (34) 
Full text Case-
control 
77 AS 
307 Controls 
Meat and meat 
products (servings 
per week) 
AS No significant difference between cases and controls. 
Median (IQR) serving per week in AS cases: 5.6 (4.2-7.0), 
controls: 5.6 (4.3-6.7) (P=0.68). 
 
AS: ankylosing spondylitis; IQR: Interquartile range; BASDAI: Bath Ankylosing Disease Activity Index;  
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Appendix 14. Summary of evidence on relationship between consumption of convenience food, cooking oil and salt and AS 
 
First 
author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants  
Exposure Outcomes Results/Conclusion 
Claudepierre 
1998 (26) 
Full text Case 
series 
293 Consumption of 
canned food, frozen 
food; Number of 
meals taken out of 
home (per week) 
BASDAI No association (no precise figures were reported) with 
canned or frozen food; 
Mean (SD) BASDAI 5.1 (2.1) for patients eating out ≤2 per 
week and 4.1 (2.1) for patients eating out >2 per week 
(P<0.001) 
Ge 2011 
(31) 
Full text Case 
series 
150 Cooking oil and salt 
consumption 
AS OR (95% CI) for interaction between IL-1F7 gene 
(rs3811047) and cooking oil (reference category: Main 
plant fats) 
Absolute plant fats 2.02 (0.732–5.575) P=0.175 
Half plants-half animal fats 4.273 (1.590-11.479) P=0.004 
Animal fats 0.306 (0.081-1.153) P=0.071 
 
OR (95% CI) for interaction between IL-1F7 gene 
(rs3811047) and salt consumption (reference category: 
Light) 
Moderate 1.0 (0.355–2.818) P=1.000 
Salty 1.523 (0.557–4.163) P=0.413 
Taşpınar 
2014 (40) 
Conference 
abstract 
Case 
series 
100 Consumption of fast 
food and salt  
BASDAI No association (p>0.05) (no precise figures were 
reported) 
 
AS: ankylosing spondylitis; BASDAI: Bath Ankylosing Disease Activity Index; OR: Odds ratio;  
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Appendix 15. Summary of evidence on relationship between probiotic and other CAM supplementation and AS 
 
First author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants 
(duration of 
follow up) 
Exposure Outcomes # Estimated effect 
 
Brophy 2008 
(28) 
Full text RCT 147 
(baseline) 
134 (follow 
up) 
(12 weeks) 
Probiotic group: 10 g lyophilized powder 
(capsule) containing live bacteria: Lactobacillus 
salivarius (CUL61) 6.25 × 109 cfu (colony 
forming units), Lactobacilllus paracasei (CUL08) 
1.25 × 109cfu, Bifidobacterium infantis (CUL34) 
1.25 × 109 cfu Bifidobacterium bifidum (CUL20) 
1.25 × 109 cfu)  
Placebo group: 10 g maltodextrin capsule 
Dose: One capsule by mouth daily  
# 0–10 scale (10 
is worst)   
 
Global wellbeing 
Disease activity  
Function 
Change in scale (95% CI); a 
positive value indicates a 
worsening in condition 
0.16 (-0.16, 0.93) 
0.20 (-0.47, 0.86) 
-0.04 (-0.50, 0.43) 
Sanges, 
2009 (36) 
Letter Uncontrolled 
treatment 
outcome 
18 (4 weeks) Lactobacillus Acidophilus and Lactobacillus 
salivarius, 2 billions 
Dose: Daily in two divided doses 
 
BASDAI 
BASFI 
VAS 
CRP 
ESR 
Mean (SD): Baseline; Follow up 
5.8 (1.5); 4 (1.8) P< 0.05 
33.6 (10); 28.6(6.3) 
58.1 (16.8); 41.5 (14.3) P< 0.05 
25.2 (11); 19.8 (6.4) 
28 (11.6); 22.5 (7.1) 
Jenks 2010 
(30) 
Full text RCT 63 (baseline) 
62 (follow 
up) 
(12 weeks) 
Probiotic group: Streptococcus salivarius K12 (1 
x 108 cfu/g), Bifidobacterium lactis LAFTI B94 (4 
x 108 cfu/g), and Lactobacillus acidophilus 
LAFTI L10 (4 x 108 cfu/g) (5.5% of the weight of 
the powder composition). The remainder of the 
formulation consisted of the excipient 
ingredients, identical to placebo. 
Placebo group: Powder of glucidex 37.6%, 
trehalose 56.49%, and vanilla flavour 0.43% 
identical in appearance, taste, and texture to the 
active probiotic treatment. 
Dose: One level spoonful (approximately 0.8 g) 
by mouth twice daily  
 
# 0–10 scale (10 
is worst)   
Global VAS 
BASDAI 
BASFI 
Pain VAS 
CRP 
ASQoL 
Change in scale (95% CI); a 
positive value indicates a 
worsening in condition 
-0.4 (-1.4, 0.7) 
-0.6 (-1.6, 0.3) 
-0.1 (-0.7, 0.6) 
0.2 (-0.8, 1.1) 
-3.5 (-7.8, 0.8) 
-0.5 (-2.0, 1.1) 
Chatfield, 
2009 (29) 
Full text Case series 75 Current CAM use (within past 3 months) 
including dietary (avoidance or inclusion of 
specific foods or supplements) 
 
ESR 
CRP 
BASDAI 
BASFI 
ASQoL 
Mean (SD) in users / non-users 
23.9 (23.4) / 27.4 (17.7) P=0.61  
21.8 (24.9) / 31.5 (48.8) P=0.29  
2.9 (2.4) / 3.2 (2.8) P=0.68  
5.3 (2.9) / 5.6 (2.4) P=0.73  
9.9 (5.3) / 8.2 (4.6) P=0.31  
42 
 
BASG  5.8 (2.6) / 5.2 (2.8) P=0.46 
Sundström 
2011 (32) 
Full text Case series 111 Herbal products, multivitamins and other food 
supplements in the past 2 weeks 
Prevalence of 
use 
32 (29%) reported consumption; 
the most common were omega-
3 (13), multivitamin and/or 
mineral (12) and iron (4) 
 
AS: ankylosing spondylitis; RCT: Randomised Clinical Trial; SD: Standard Deviation; CI: Confidence Interval; BASDAI: Bath Ankylosing Disease Activity Index; 
ASQoL: AS Quality of Life; ESR: Erythrocyte Sedimentation Rate; CRP: C-reactive protein; SF-36: 36-Item Short Form Health Survey; -BASDAI: Bath Ankylosing 
Disease Activity Index; BASFI: Bath Ankylosing Functional Index; BASG: Bath AS Patient Global Score; VAS: Visual Analogue Scale 
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Appendix 16. Summary of evidence on relationship between specific diet and AS 
 
First 
author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants  
Exposure Outcomes Results/Conclusion 
Haugen, 
1991 (25) 
 
Full text Case 
series 
87 Specific diet Self-reported 
symptoms 
68 (78%) believed that diet influenced disease symptoms; 
29 (43%) of these believed that diet had great influence 
(VAS >5); 
14 (16%) had previously fasted on their own initiative to 
ameliorate disease symptoms and the majority reported 
less pain, less stiffness and less joint swelling; 
19 (22%) tried dietary therapy in an attempt to alleviate 
symptoms; 
36% reported increased swelling of the joint associated 
with certain types of food (no information available) 
Sundström 
2011 (32) 
Full text Case 
series 
111 Type of food Self-reported 
symptoms 
7 (6%) reported that they experienced aggravated 
arthralgia or AS symptoms associated with particular 
foodstuff; 
 
AS: ankylosing spondylitis; VAS: Visual Analogies Scale 
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Appendix 17. Summary of evidence on relationship between nutrient intake and AS 
 
First 
author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants  
Exposure Outcomes Results/Conclusion 
Sundström 
2011 (32) 
Full text Case 
series 
 
111 Energy intake (kJ); 
Protein, %E 
Carbohydrate, %E  
Fibre, grams 
 
Fat, %E 
Saturated fats, %E 
 
BASDAI No correlation (no precise figures were reported) 
 
 
 
Women only: 
rs=−0.43, P<0.05 
rs=−0.50, P<0.01 
Sundström, 
2012 (33) 
Full text Case 
series 
 
66  
Protein, %E 
Carbohydrate, %E  
Fat, %E 
 
 
BASDAI, 
ESR, 
hsCRP 
(BASDAI, ESR, hsCRP respectively); P>0.05 
rs= –0.17, rs=–0.06, rs= 0.01  
rs= –0.12, rs= 0.22, rs= 0.10 
rs= 0.10, rs= –0.21, rs= 0.04 
Sundström 
2014 (34) 
Full text Case-
control 
77 AS 
307 Controls 
 
Energy intake (kcal) 
Protein, E% 
Carbohydrate, E% 
Fat, E% 
Fibre/energy, 
grams/1000 kcal 
 
AS Mean (SD)  
Cases: 1940 (503), Controls: 1819 (510) p<0.05 
Cases: 15 (2.0), Controls: 15 (2.2) p=0.73 
Cases: 48 (5.8), Controls: 47 (6.5) p=0.11 
Cases: 34 (5.6), Controls: 35 (6.2) p=0.07 
Cases: 11 (3.0), Controls: 11 (3.3) p=0.85 
 
%E: % of energy intake; AS: ankylosing spondylitis; BASDAI: Bath Ankylosing Disease Activity Index; ESR: Erythrocyte Sedimentation Rate; CRP: C-
reactive protein; SD: Standard Deviation 
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Appendix 18. Summary of evidence on relationship between dietary fatty acids intake and AS 
 
First 
author, 
publication 
year 
Type of 
publication 
Type of 
study 
N of 
participants  
Exposure Outcomes Results/Conclusion 
Sundström 
2011 (32) 
Full text Case 
series 
 
111 Saturated fatty acids, %E 
Polyunsaturated fatty acids, %E 
Long-chain omega-3 fatty acids, %E 
Omega-3 fatty acids, %E 
 
BASDAI No correlation (no precise figures were 
reported) 
 
Sundström, 
2012 (33) 
Full text Case 
series 
 
66  
Saturated fatty acids, %E 
Linoleic acid, %E 
Alpha-linolenic acid, %E 
Polyunsaturated fatty acids, %E 
Long-chain omega-3 fatty acids, %E 
 
 
BASDAI, 
ESR, hsCRP 
(BASDAI, ESR, hsCRP respectively) 
rs= –0.01, rs= 0.00, rs= 0.10 
rs= 0.11, rs= –0.24, rs= –0.10 
rs= 0.06, rs= –0.22, rs= 0.00 
rs= 0.10, rs= –0.25 (P<0.005), rs= –0.11 
rs= 0.06, rs= –0.27 (P<0.005), rs= –0.17 
Sundström 
2014 (34) 
Full text Case-
control 
77 AS 
307 Controls 
 
Saturated fatty acids, E% 
Mono-unsaturated fatty acids, E% 
Polyunsaturated fatty acids, E% 
Linoleic acid, E% 
Alpha-linolenic acid, E% 
Long-chain omega-3 fatty acids, E% 
AS Mean (SD)  
Cases: 14 (2.9), Controls: 14 (3.2) p=0.26 
Cases: 12 (2.2), Controls:12 (2.3) p=0.07 
Cases: 5.7 (1.6), Controls: 6.0 (2.1) p=0.26 
Cases: 4.2 (1.4), Controls: 4.4 (1.8) p=0.47 
Cases: 0.8 (0.2), Controls: 0.8 (0.3) p=0.52 
Cases: 0.09 (0.06), Controls: 0.11 (0.08) 
p=0.16 
 
 
 
%E: % of energy intake; AS: ankylosing spondylitis; BASDAI: Bath Ankylosing Disease Activity Index; ESR: Erythrocyte Sedimentation Rate; CRP: C-
reactive protein; SD: Standard Deviation 
 
 
